Related Experiment Video
Updated: Aug 15, 2026

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 9, 2014
Review of the Varilrix varicella vaccine
1Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China. ssschiu@hkucc.hku.hk
Abstract:
Varicella zoster virus causes an acute infection that affects most children globally, but the age of infection can be greater in residents of tropical areas. It has generally been considered a mild disease, although there are accumulating data to show that it can cause significant morbidity and mortality in immunocompetent as well as immunocompromised children and adults. Oka-strain live attenuated varicella vaccines were developed in the 1970s. Varilrix developed by GlaxoSmithKline Biologicals (Rixensart, Belgium), is one of the vaccines produced and marketed in over 80 countries. Similar to the other Oka-strain vaccines, Varilrix is safe, immunogenic and efficacious in both immunocompromised and immunocompetent children and adults.
More Related Videos
Related Concept Videos
Chickenpox
Vaccinations
Vaccines
Respiratory Syncytial Virus Disease
Poliomyelitis
Smallpox

